Synovics Pharmaceuticals, Inc.
SYVC
$0.00
$0.000.00%
OTC PK
| 07/31/2009 | 04/30/2009 | 01/31/2009 | 10/31/2008 | 07/31/2008 | |
|---|---|---|---|---|---|
| Revenue | 19.09M | 25.23M | 28.54M | 25.96M | 23.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.09M | 25.23M | 28.54M | 25.96M | 23.42M |
| Cost of Revenue | 14.63M | 17.18M | 18.22M | 16.99M | 16.15M |
| Gross Profit | 4.47M | 8.05M | 10.32M | 8.97M | 7.27M |
| SG&A Expenses | 7.62M | 10.12M | 11.34M | 10.28M | 11.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.41M | 28.46M | 30.67M | 28.44M | 28.65M |
| Operating Income | -4.32M | -3.23M | -2.13M | -2.48M | -5.23M |
| Income Before Tax | -5.04M | -2.53M | -2.88M | -4.01M | -8.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.04 | -2.53 | -2.88 | -4.01 | -8.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.04M | -2.53M | -2.88M | -4.01M | -8.90M |
| EBIT | -4.32M | -3.23M | -2.13M | -2.48M | -5.23M |
| EBITDA | -3.64M | -2.62M | -1.51M | -1.87M | -4.56M |
| EPS Basic | -0.17 | -0.09 | -0.14 | -0.19 | -0.44 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.14 | -0.18 | -0.32 |
| EPS Diluted | -0.17 | -0.09 | -0.14 | -0.20 | -0.45 |
| Normalized Diluted EPS | -0.11 | -0.10 | -0.13 | -0.16 | -0.31 |
| Average Basic Shares Outstanding | 112.85M | 111.45M | 103.88M | 99.08M | 92.25M |
| Average Diluted Shares Outstanding | 112.85M | 126.45M | 118.88M | 114.08M | 107.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |